Anthony Parravani , MD

Associate Professor of Nephrology
Assistant Professor

Organization:

West Virginia University School of Medicine

Department:

Medicine

Classification:

Faculty

• MD, Ross University School of Medicine

Parravani A, Pellegrino B, Cook L. , MacKay K. Ethylene glycol intoxication: Disparate findings of immediate versus delayed presentation. WV Medical Journal 2006, 10232-34.

Academic Awards:

2005    Patient Care Award

2005    Best Teaching Resident

2005    Community Service Award

2004    Nominated Mrs. Sakarba V. Dedhia Outstanding House Staff

2004    Patient Care Award

2004    Best Teaching Resident

Professional Societies:

American Society of Nephrology

Renal Physicians Association

National Kidney Foundation

American College of Physicians

Dr. Anthony Parravani is currently an Assistant Professor of Medicine in the Division of Nephrology in the Department of Medicine. He graduated from Ross University School of Medicine in 2002 and completed his residency in Internal Medicine at West Virginia University. He completed his fellowship in Nephrology also at West Virginia University, joining the faculty in the Division of Nephrology in 2007. He has served as Associate Program Director for Internal Medicine from 2008 to 2014. He is currently the Medical Director of Grafton Dialysis Unit and Inpatient Dialysis Unit of West Virginia University Medicine. Dr. Parravani’s interests include Acute Kidney Injury, Continuous Renal Replacement Therapy and Nephrolithiasis.

Research:

Investigator-initiated- 2007-2009. Prospective, randomized trial of low dose 4.4% sodium citrate versus standard heparin as a catheter lock solution in patients undergoing hemodialysis with a transcutaneous cuff catheter. Role: Principal-investigator (PI)

Industry Supported: Hoffman-La Roche-2007-2009. Open-label, multi-center, study to document the efficacy, safety, and tolerability of long-term administration of R00503821 in patients with chronic renal anemia. Role: Sub-investigator (Sub-)

Industry Supported: Amgen Pharmaceuticals: 2007-2009. Evaluation of cinacalcet HCL therapy to lower cardio vascular events. Role: Sub-Investigator (Sub-I)

Industry Supported: Affymax Pharmaceuticals: 2008 —2010. Phase 3, randomized, active-controlled, open-label, multi-center, study of the safety and efficacy of AF37702 injection for the correction of anemia in patients with chronic renal failure not on dialysis and not on an erythropoietin stimulating agent. Role: Sub-Investigator (Sub-I)

Industry Supported: Affymax Pharmaceuticals: 2008-2010. Phase 3, randomized, active-controlled, open-label, multi-center, study of the safety and efficacy of AF37702 injection for the maintenance treatment of anemia in hemodialysis patients previously treated with epoetin alfa Role: Sub-Investigator (Sub-I)

Industry Supported: Kurhea Incorporated: 2009-2012. Phase 3, randomized, double-blind, placebo-controlled study of AST-120 for prevention of CKD progression in patients with moderate to severe CKD, including assessment of quality of life. Role: Sub-Investigator (Sub-I)

Industry Supported: Genzyme Incorporated: 2008-2012. Fabry Disease Registry. Role: Sub-Investigator (Sub-I)

Industry Supported: Amgen Pharmaceuticals: 2007-2009. Phase 2, randomized, double-blind, placebo-controlled, parallel group, fixed dose study of AMG223 in subjects with chronic kidney disease on hemodialysis with hyperphosphatemia Role: Sub-Investigator (Sub-I)

Industry Supported: (DOPPS IV) 2010-2012. Dialysis Outcomes and Practice Patterns Study IV Role: Sub Investigator (Sub-I)

Industry Supported: REATA study 201 1-2012. Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes. Role: Sub-Investigator (Sub-I)

Industry Supported: (DOPPSV) 2013-2015. Dialysis Outcomes and Practice Patterns Study V. Role: Sub-Investigator (Sub-I)

Industry Supported: ABBVIE Protocol Ml 1-352 (SONAR Study) 2013-present Role: Sub-investigator (Sub-I)

Grant: Utility of an Integrated Diagnostic Tool for Outcomes in Patients 2014-present With Stages 4 and 5 Chronic Kidney Disease (CKD) Role: Sub-Investigator (Sub-I)

Industry Supported: (DOPPS VI) 2015-present. Dialysis Outcomes and Practice Patterns Study VI Role: Sub-Investigator (Sub-I)

Industry Supported: (CKDOPPS) 2014-present. Chronic Kidney Disease Outcomes and Practice Patterns Study Role: Sub-investigator (Sub-I)

Industry Supported: Otsuka Protocol 156-13-210 (REPRISE Study) 2014-present. Phase 3b, Multi-Center, Randomized-Withdrawal, Placebo-controlled, Double-Blind, Parallel-Group Trial to Compare the Efficacy andSafety of Tolvaptan (45-120mg/day, split dose) in Subjects with Chronic Kidney Disease Between Late Stage 2 to Early Stage 4 Due to Autosomal Dominant Polycystic Kidney Disease. Role: Sub-Investigator (Sub-I)

Industry Supported: Fibrogen (FG-4592 Study) 2015-present. Phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat for the treatment of Anemia in CKD Patients not on Dialysis. Role: Sub-Investigator (Sub-I)

Industry Supported: OTSUKA (Protocol 156-13-211) 2015-present. Phase 3b, Multi-Center, Open-label, Trial to Evaluate the Long term Safety of Titrated Immediate Release Tolvaptan (30-120mg/day, split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease. Role: Sub-Investigator (Sub-I)

 

Medical Specialties

• Nephrology/Kidney Disease

Board Certifications

• Internal Medicine, American Board of Internal Medicine
• Nephrology, American Board of Internal Medicine

Special Training

• Residency, Internal Medicine
  WVU Department of Medicine
• Fellowship, Nephrology
  WVU Department of Medicine